Home > Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare part D beneficiaries.

Hernandez, Inmaculada and He, Meiqi and Brooks, Maria M . (2018) Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare part D beneficiaries. American Medical Association. JAMA Network Open, 1 (2) 180919. 10.1001/jamanetworkopen.2018.0919

URL: https://jamanetwork.com/journals/jamanetworkopen/f...

Question: How does the risk of overdose change with the number of days with concurrent opioid and benzodiazepine use?

Findings: In this cohort study of US Medicare data, the overdose risk associated with concurrent benzodiazepine use changed over time. Concurrent benzodiazepine use was associated with a 5-fold increase in the risk of opioid-related overdose during the initial 90 days and an increase of 1.87 times on days 91 to 180.

Meaning: Policy interventions should focus on preventing concurrent opioid and benzodiazepine use in the first place instead of reducing the length of concurrent use. Patients using both medications should be closely monitored, particularly during the first days of concurrent use.


Item Type:Evidence resource
Drug Type:Opioid
Intervention Type:AOD disorder, AOD disorder harm reduction
Date:June 2018
Pages:180919
Publisher:American Medical Association
Volume:1
Number:2
EndNote:View
Subjects:B Substances > Sedatives or tranquillisers (CNS depressants) > Benzodiazepine
B Substances > Opioids (opiates)
G Health and disease > Substance use disorder > Multiple substance use (Poly-drug /Poly-substance)
G Health and disease > Substance use disorder > Drug use > Drug intoxication > Poisoning (overdose)
P Demography, epidemiology, and history > Population dynamics > Substance related mortality / death
VA Geographic area > United States

Repository Staff Only: item control page